VRTX250110C535000
- 0.10
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Vertex Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Vertex Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $460
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Cuts Target Price to $456
Wells Fargo Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $460
Vertex Pharmaceuticals: Hold Rating Amid Mixed Results for Suzetrigine in LSR and Optimistic Prospects in Acute Pain
RBC Lifts Price Target on Vertex Pharmaceuticals to $401 From $400, Keeps Sector Perform Rating
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $441
Bernstein Remains a Hold on Vertex Pharmaceuticals (VRTX)
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $460
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $430 to $525
RBC Capital Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank
Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
TD Cowen Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $500
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Vertex Pharmaceuticals (VRTX) and Ascendis Pharma (ASND)
Barclays Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $418